News

Adial Pharmaceuticals Yields Encouraging Results for AD04 in AUD

Adial Pharmaceuticals Yields Encouraging Results for AD04 in AUD

Adial Pharmaceuticals Reports Promising Findings from AD04 Study

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) has exciting news to share regarding the latest phase of its ongoing research into AD04, a groundbreaking treatment aimed at those facing Alcohol Use Disorder (AUD). The company has finished a critical pharmacokinetics study of AD04, which serves as a crucial stepping stone towards advancing this innovative therapy. This development signifies an essential milestone for the company as it gears up for future clinical trials and discussions with regulatory bodies.

Key Outcomes from the Pharmacokinetics Study

The pharmacokinetics study has confirmed important findings, including the relative bioavailability of AD04 compared to standard treatments and the dose-dependent response. The study, which included a total of 30 healthy adult volunteers, aimed to evaluate how the drug's absorption and distribution occur at different dosages. In the trial, participants were assigned to one of two cohorts where they received varying doses of AD04 and assessed its performance against marketed ondansetron. Results indicated that the 0.33mg dose leads to a lower exposure compared to a 4mg standard dose while still maintaining a solid pharmacokinetic profile. The study also confirmed that AD04 could be administered comfortably in either fed or fasted states, which adds to its convenience as a therapy for AUD.

Next Steps for Adial Pharmaceuticals

Cary Claiborne, the President and CEO of Adial Pharmaceuticals, shared optimistic news about the study's completion. According to him, the data collected are crucial for refining the design of their upcoming Phase 3 trial. The company is eager to integrate this newfound understanding to enhance the efficacy and safety of AD04 for patients suffering from AUD. These findings align with expectations laid out in previous regulatory discussions, marking a notable advancement in the development process. Furthermore, the results will pave the way for an application for regulatory approval through the 505(b)(2) process with the FDA.

About AD04 and Its Mechanism

AD04 operates uniquely on the 5HT3 pathway, offering a new option for individuals battling alcohol cravings. Its therapeutic approach stands out as it directly targets genetically identified receptor variabilities, which means it could be particularly effective for patients with certain genetic profiles. Notably, individuals carrying specific mutations within the 5HT3 receptor gene may see significant improvements in alcohol consumption through the use of AD04. Past clinical trials have shown that AD04's side effect profile is comparable to that of a placebo, reinforcing the belief that it is both safe and tolerable for patients.

The Role of Diagnostic Testing

Adial's strategy includes developing a companion diagnostic test aimed at identifying the right candidates for AD04 treatment. This test determines genetic predispositions and ensures that the drug reaches those who are most likely to benefit from it. The company utilized this test during its ONWARD clinical trial and plans to make it accessible at the time AD04 hits the market. By tailoring treatments to meet the specific needs of a patient population, Adial hopes to revolutionize AUD care and improve patient outcomes greatly.

Adial Pharmaceuticals Overview

Adial Pharmaceuticals, located in Glen Allen, Virginia, is a clinical-stage biopharmaceutical company dedicated to developing effective solutions for addiction and related disorders. Their flagship product, AD04, targets Alcohol Use Disorder and is built upon a foundation of extensive research and regulatory rigor. The encouraging results of AD04 have opened doors for further investigations into its potential effects on other addictions, including Opioid Use Disorder and gambling. This multifaceted approach underscores Adial's commitment to addressing pressing health issues across various domains.

Frequently Asked Questions

What are the latest results of the AD04 pharmacokinetics study?

The study confirmed the relative bioavailability of AD04, showing promising pharmacokinetic responses in participants while yielding safe tolerability.

How does AD04 work for treating Alcohol Use Disorder?

AD04 targets the 5HT3 pathway and is designed to mitigate alcohol cravings, particularly for individuals with specific genetic mutations.

What role does genetic testing play in the AD04 treatment process?

A companion diagnostic test identifies patients likely to respond best to AD04, enhancing treatment efficacy and tailoring therapeutic approaches.

What are the future plans for Adial Pharmaceuticals regarding AD04?

Adial aims to engage with the FDA to discuss the study’s findings and further refine their Phase 3 trial protocols for AD04.

Can AD04 be taken with or without food?

Yes, the study demonstrated that AD04 can be effectively administered in both fed and fasted states.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 0

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

Epson Robots Unveils Cutting-Edge Automation Tech at Expo

Updated Category News Views 360

Innovative Automation Solutions by Epson Robots Epson Robots is set to showcase its latest high-performance automation solutions at an upcoming major tradeshow. The focus will be on the exciting advancements in the SCARA and 6-Axis robots, which are recognized globally for their efficiency and precision in various industries. Exciting New Product Launches At the event,...

Continue Reading
Rexel Reports Fourth Quarter Growth Amid Market Challenges

Updated Category News Views 313

Rexel's Financial Performance Overview Rexel has released its fourth quarter (Q4) and full year (FY) financial results, showcasing strong performance amid challenging market conditions. The company's FY 2024 sales reached €19,285.1 million, reflecting a modest year-on-year increase of 0.7% on a reported basis. This growth narrative underscores Rexel's effective...

Continue Reading
Monster Beverage Sees Gains in 2025 First Quarter Results

Updated Category News Views 313

Monster Beverage's Impressive First Quarter Growth 2025 First Quarter Highlights The financial landscape for Monster Beverage Corporation (NASDAQ: MNST) revealed compelling growth in the first quarter of 2025. Gross profit as a percentage of net sales improved significantly, reaching 56.5 percent. The company reported an operating income increase of 5.1 percent, totaling...

Continue Reading
Transforming Metastatic HR+/HER2- Breast Cancer Care Innovations

Updated Category News Views 215

Transforming Treatment Strategies for Metastatic HR+/HER2- Breast Cancer In recent years, the landscape of metastatic HR+/HER2- breast cancer treatment has evolved dramatically. With innovative therapies coming to the forefront, patients now have access to a wider range of treatment options that aim to improve survival rates and quality of life. The rise of targeted...

Continue Reading
Oil Price Surge Driven by Manufacturing Growth in China

Updated Category News Views 193

Understanding the Recent Trends in Oil Prices Oil prices experienced an uptick recently, driven by promising signs from China's manufacturing sector. Reports reveal that China's factory activity demonstrated growth in December, marking it as a significant development in the global oil landscape. However, despite this positive news, oil prices are on a trajectory to finish...

Continue Reading